ArticleEuropean radiology2026
Comparison of automated breast ultrasound and hand-held breast ultrasound in preoperative evaluation of early-stage breast cancer: a multicenter prospective study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare automated breast ultrasound (ABUS) and handheld breast ultrasound (HHUS) as adjuncts to digital mammography (DM) for preoperative assessment of local tumor extent in women with newly diagnosed early-stage breast cancer. MATERIALS AND
methodsIn this prospective study conducted at three institutions, women with newly diagnosed early-stage breast cancer and no palpable axillary nodes scheduled for surgery underwent ABUS and HHUS adjunct to DM between Oct 2019 and Apr 2021. The primary outcome was the sensitivity of ABUS with DM (ABUS/DM) and HHUS with DM (HHUS/DM) for detecting additional ipsilateral or contralateral cancers beyond the index cancer. ABUS/DM was evaluated for noninferiority with a prespecified margin of 5%. Specificity was assessed as a secondary outcome.
resultsA total of 659 patients (mean age, 50.5 ± 9 years) were included. Seventy-nine patients (12.0%) had additional cancers: 64 ipsilateral (51 multifocal, 13 multicentric) and 15 contralateral. For index cancers, both ABUS/DM and HHUS/DM achieved 100% detection. ABUS/DM showed noninferior sensitivity to HHUS/DM for additional ipsilateral cancers (71.9% vs. 75.0%; p = 0.617) and higher sensitivity than HHUS/DM for contralateral cancers (86.7% vs. 60.0%; p = 0.046). Specificity did not differ significantly between ABUS/DM and HHUS/DM for additional ipsilateral (97.7% vs. 97.0%; p = 0.317) or contralateral (97.8% vs. 98.3%; p = 0.467) cancers.
conclusionABUS/DM showed noninferior sensitivity to HHUS/DM, with similar specificity for detecting additional ipsilateral and contralateral breast cancers in early-stage breast cancer. ABUS may serve as a feasible alternative to HHUS for preoperative staging in early-stage breast cancer. KEY POINTS: Question Is automated breast ultrasound (ABUS) noninferior to handheld ultrasound (HHUS), each with digital mammography (DM), in preoperative staging of tumor extent in early-stage breast cancer? Findings ABUS/DM demonstrated noninferior sensitivity to HHUS/DM, with similar specificity for detecting additional ipsilateral and contralateral cancers in early-stage breast cancer. Clinical relevance ABUS may serve as a feasible alternative to HHUS for preoperative staging in early-stage breast cancer, particularly in clinical settings where the HHUS use is constrained by limited staffing resources and time restrictions.
Indexed as
Identifiers
42270856What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.